EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
Abstract
Authors
M.F. Mørup V. Taieb D. Willems M. Rose M. Lamotte L. Gerlier H. Thom